A retrospective comparative outcome analysis following systemic therapy in Mycosis Fungoides and Sezary Syndrome

Conclusions: With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced‐stage disease. Therefore, clinical trial participation with novel agents should be encouraged. This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Research Article Source Type: research